INTEGRAL DIAGNOSTICS LIMITED (IDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IDX

IDX - INTEGRAL DIAGNOSTICS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 4.21
Index: ASX300 | ALL-ORDS

Integral Diagnostics is a diagnostic imaging provider operating in Australia and New Zealand. Following its 2024 merger with Capitol Health, the combined group operates about 155 clinics with more than 350 radiologists and 3,000 employees.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.27

27 Aug
2026

-0.060

OPEN

$2.27

-2.58%

HIGH

$2.27

2,039,066

LOW

$2.24

TARGET
$3.325 46.5% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . ALC . BMT . DOC . EBO . HLS . M7T . MPL . MVF . NHF . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
IDX: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 5.9 13.3 xxx
DPS (cps) xxx 9.3 9.5 xxx
EPS Growth xxx 100.0% 100.0% xxx
DPS Growth xxx 43.1% 2.2% xxx
PE Ratio xxx N/A 16.9 xxx
Dividend Yield xxx N/A 4.2% xxx
Div Pay Ratio(%) xxx 158.2% 71.5% xxx

Dividend yield today if purchased 3 years ago: 3.11%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 4.13

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 28/08 - ex-div 6.00c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx5.9
DPS All xxxxxxxxxxxxxxx9.3
Sales/Revenue xxxxxxxxxxxxxxx788.6 M
Book Value Per Share xxxxxxxxxxxxxxx181.5
Net Operating Cash Flow xxxxxxxxxxxxxxx95.2 M
Net Profit Margin xxxxxxxxxxxxxxx2.78 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx3.20 %
Return on Invested Capital xxxxxxxxxxxxxxx1.75 %
Return on Assets xxxxxxxxxxxxxxx1.52 %
Return on Equity xxxxxxxxxxxxxxx3.20 %
Return on Total Capital xxxxxxxxxxxxxxx5.29 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx19.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx21 M
Long Term Debt xxxxxxxxxxxxxxx576 M
Total Debt xxxxxxxxxxxxxxx597 M
Goodwill - Gross xxxxxxxxxxxxxxx796 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx51 M
Price To Book Value xxxxxxxxxxxxxxx1.10

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx49.6 M
Capex % of Sales xxxxxxxxxxxxxxx6.29 %
Cost of Goods Sold xxxxxxxxxxxxxxx620 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx101 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx4 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

26/08/2026

1

Buy

$3.30

45.37%

Ord Minnett raises its target for Integral Diagnostics by 10c to $3.30 following an in-line FY26 result. Buy rating maintained. A material re-rating is anticipated should management improve organic growth, margins and the balance sheet.

The broker explains new management targets a margin above 21% in FY27 through revenue management, cost efficiencies, AI and a review of lower-margin clinics. A strategic review of New Zealand is also commencing.

Adjusted earnings (EBITDA) for FY26 rose 30% to $165m, while the EBITDA margin expanded 80bps to 20.9%, supported by lower labour costs, the analysts highlight.

FORECAST
Ord Minnett forecasts a full year FY27 dividend of 9.50 cents and EPS of 13.10 cents.
Ord Minnett forecasts a full year FY28 dividend of 10.60 cents and EPS of 15.10 cents.

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

04/03/2026

1

Buy

$2.57

13.22%

Integral Diagnostics' 1H26 results were an authentic beat, Canaccord Genuity suggests, but, predictably, the result attracted scrutiny as to what was 'in' and what was 'out' of underlying earnings - and that drove the stock down.

The broker believes this misses the entire point of the Integral Diagnostics investment, which has always been about the business' corporate appeal, and the view that large scale consolidation in Australian radiology is inevitable.

That immutable appeal is only amplified by the Capitol Health merger, in Canaccord's view, which continues to prove that more can be done with less. The combination was and is a structural beneficiary of MRI deregulation.

Trade buyers in healthcare services can and do (typically) pay more than what ASX market participants pay for high quality, well-run healthcare services exposure, Canaccord notes. Target falls to $2.57 from $3.20, Buy retained.

FORECAST
Canaccord Genuity forecasts a full year FY27 dividend of 9.00 cents and EPS of 15.00 cents.
Access Extra Coverage Research History >

IDX STOCK CHART

FNArena News on IDX

1
Australian Broker Call *Extra* Edition – Aug 27, 2026

Aug 27 2026 - Daily Market Reports
2
FNArena Corporate Results Monitor – 26-08-2026

Aug 26 2026 - Australia
3
Rudi’s View: Upside Risk In Crowded Shorts

Aug 12 2026 - Rudi's View
4
Rudi’s View: That’s The Way Markets Crumble

Aug 06 2026 - Rudi's View
5
Treasure Chest: Beware Aussie Healthcare

Jul 17 2026 - Treasure Chest

Latest Healthcare services News

1
Treasure Chest: Beware Aussie Healthcare

Jul 17 2026 - Treasure Chest
2
Major UK Win Highlights Alcidion’s Potential

May 27 2026 - Small Caps
3
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
4
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
5
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
6
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
7
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
8
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
9
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
10
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps